Symbiotec Pharmalab Ltd IPO - Check Issue Date, Price, Lot Size & Details with BlinkX.

Symbiotec Pharmalab Ltd IPO

We are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms-organic chemistry, biotechnology and complex injectables. We have a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) in volume terms in Fiscal 2025, with a global volume market share of 36.2% in corticosteroid and 44.2% in steroidalhormone APIs. We have leveraged our capabilities to operate as a contract development and manufacturing organisation (CDMO) for specialty pharmaceutical and nutraceutical companies.

Symbiotec Pharmalab Ltd IPO Details

Total Shares Offered

₹ 1,77,83,400

Offer to Public

1,62,65,182

Retail Max (Shares)

₹ 62,13,563

Pre Issue Promoters Holding

₹ 2,28,41,312

Exchange

BSE

Issue size

₹ 1757 Cr

IPO Open Date

Aug 24, 2026

Close Date

Aug 27, 2026

Lot Size

Min Investment

₹ 14,070

Issue Type

Book Building

Listing Date

Sep 1, 2026

Symbiotec Pharmalab Ltd IPO Dates

Aug 24, 2026

Opening date

Aug 27, 2026

Closing date

Aug 28, 2026

Basis of Allotment

Aug 28, 2026

Initiation of Refunds

Aug 31, 2026

Credit of Shares

Sep 1, 2026

Listing date

Details

Sector	Type
Sector	Pharmaceuticals - Indian - Bulk Drugs & Formln
Sub Sector	NA
Issue Type	Book Building

Subscription Status

*Values are in Lakhs

Investor Type	Subscription Times	Shares Offered*
QIB	0x	8876518
NII	0x	2662955
Retail	0x	6213563
Employee	0x	30364
Total	0x	17783400

Investor Type

QIB

NII

Retail

Employee

Total

Subscription Times

8876518

2662955

6213563

30364

17783400

Symbiotec Pharmalab Ltd Financial Status

Income Statement

Particulars (In Rs. Crores)

Balance Sheet

Particulars (In Rs. Crores)

Particulars (in Rs. Crores)	FY23	FY22	FY21
Revenue from operations	751.55	716.25	566.51
EBITDA	272.74	192.42	47.46
PAT	145.83	88.95	-22.66
Total Assets	480.14	504.32	386.62
Share Capital	10.94	10.94	10.94
Total Borrowings	320.06	91.73	137.03
Operating Activities (Net Cash)	184.19	126.21	4.96
Investing Activities (Net Cash)	-14.85	22.89	-8.30
Financing Activities (Net Cash)	320.06	91.73	137.03
Net Cashflow	22.59	6.27	2.83

About Symbiotec Pharmalab Ltd

Our Company was incorporated as `Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025 and a special resolution dated September 12, 2025 passed in the extraordinary general meeting of our Shareholders. Consequently the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.

The global API market is expected to grow at a 7.0% CAGR from 2024, reaching US$ 399.9 billion by 2029. The classical fermentation API market was valued at US$ 464.7 million in 2024 and is expected to grow at a CAGR of 0.5% to 2.5% between 2024 and 2029. The corticosteroid API market was valued at US$ 414.5 million in 2024, and it is estimated to grow at a moderate CAGR of 1.5 to 3.2% between 2024 and 2029. Further, CDMOs play a vital role in the pharmaceutical and biotechnology industries. The CMDO market is projected to grow at an 8.1% CAGR from 2024 to 2029, reaching US$ 190.2 billion.

Peer Comparison:

Symbiotec Pharmalab Pvt Ltd
Concord Biotech Limited
Divi's Laboratories Limited
Cohance Lifesciences Limited
Laurus Labs Limited

Symbiotec Pharmalab Ltd Key Points

Strengths

Global leadership in corticosteroid and steroidal hormone APIs.

Long-standing relationships with domestic and global customer base.

Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record.

Continuous investment in R&D, with leading technological capabilities among Indian peers.

Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings.

Risk

The company derives almost all of its revenue from the sale of APIs, which collectively constituted 96.07%, 99.10% and 100.00% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Further, its top five APIs constituted 62.27%, 63.16% and 60.37% of the company's revenue from operations in Fiscals 2026, 2025 and 2024, respectively. Any reduction in demand for APIs, and its top products in particular, or disruption in production, could have an adverse effect on the company's business, results of operations, financial condition and cash flows.

The company's manufacturing facilities is subject to periodic inspections and audits by regulatory authorities and its customers. Any manufacturing or quality control failures may subject it to regulatory action, damage the company's reputation and have an adverse effect on its business, results of operations, financial condition and cash flows.

The company exports its products to various countries and the company's revenue from external customers outside India as per Ind AS 108 - Operating Segments represented 67.04%, 55.19% and 59.97% of its revenue from operations in Fiscals 2026, 2025 and 2024, respectively. The company's inability to handle risks associated with its export sales could adversely affect the company's sales to customers in foreign countries, its results of operations, financial condition and cash flows.

Strategy

Build on our global leadership by expanding our product portfolio across steroidal-hormones in our own API and ingredients business.

Build on fermentation capabilities and expand biotechnology offerings such as GLP-1 and Insulin.

Commercialize complex injectables through differentiated drug device combinations.

Scale up our diverse CDMO offerings based on our three interlinked differentiated platform technologies.

Continue to invest in new technologies, R&D for optimising products, building on historical innovation ethos.

How To Apply for Symbiotec Pharmalab Ltd IPO Online?

Step 1:

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

FAQs on IPO (Initial Public Offering)

What is the issue size of the Symbiotec Pharmalab Ltd IPO?

Symbiotec Pharmalab Ltd's IPO offers shares for up to 150 It begins on Aug 24, 2026 and ends on Aug 27, 2026.

What is the price of the Symbiotec Pharmalab Ltd IPO?

The price of Symbiotec Pharmalab Ltd IPO ranges between ₹938 to ₹988 per share.

What are the open and close dates for the Symbiotec Pharmalab Ltd IPO?

The Symbiotec Pharmalab Ltd IPO opens on Aug 24, 2026 and closes on Aug 27, 2026.

When will the Symbiotec Pharmalab Ltd IPO be allotted?

The allotment for the Symbiotec Pharmalab Ltd IPO will be finalised on Aug 28, 2026. The shares will be listed on BSE and NSE on Sep 1, 2026.

What is the minimum lot size required for Symbiotec Pharmalab Ltd IPO?

The minimum lot size for Symbiotec Pharmalab Ltd IPO is 15 shares, priced between ₹938 to ₹988 per share.

What is the GMP of Symbiotec Pharmalab Ltd IPO?

The GMP (Grey Market Premium) of Symbiotec Pharmalab Ltd IPO fluctuates based on market demand and sentiment.

How do you check the allotment status of Symbiotec Pharmalab Ltd IPO?

To check the allotment status of Symbiotec Pharmalab Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

Where is the Symbiotec Pharmalab Ltd IPO getting listed?

The Symbiotec Pharmalab Ltd IPO is getting listed on the BSE and NSE. Bidding opens on Aug 24, 2026, and closes on Aug 27, 2026. The allotment is finalised on Aug 28, 2026.

How do you apply for the Symbiotec Pharmalab Ltd IPO?

To apply for the Symbiotec Pharmalab Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.